标题
Selinexor: First Global Approval
作者
关键词
-
出版物
DRUGS
Volume 79, Issue 13, Pages 1485-1494
出版商
Springer Science and Business Media LLC
发表日期
2019-08-19
DOI
10.1007/s40265-019-01188-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
- (2019) Andrzej J. Jakubowiak et al. BRITISH JOURNAL OF HAEMATOLOGY
- Efficacy and safety of selinexor in recurrent glioblastoma.
- (2019) Andrew B. Lassman et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer
- (2019) Michael Shafique et al. ONCOLOGIST
- A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
- (2019) N. Kalakonda et al. HEMATOLOGICAL ONCOLOGY
- Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma
- (2018) Ujjawal H. Gandhi et al. Clinical Lymphoma Myeloma & Leukemia
- Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
- (2018) Dan T. Vogl et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer
- (2018) Xiao X. Wei et al. ONCOLOGIST
- Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death
- (2018) Christian Argueta et al. Oncotarget
- Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
- (2018) Trinayan Kashyap et al. Oncotarget
- Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM)
- (2018) Sundar Jagannath et al. Clinical Lymphoma Myeloma & Leukemia
- A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).
- (2018) Sosana Delimpasi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1b study of selinexor, a first in class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).
- (2018) Eoghan Ruadh Malone et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia.
- (2018) Bhavana Bhatnagar et al. JOURNAL OF CLINICAL ONCOLOGY
- Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
- (2018) Nizar J. Bahlis et al. BLOOD
- Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
- (2017) Barbara Muz et al. Translational Oncology
- Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone
- (2016) Irfana Muqbil et al. CANCER LETTERS
- XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells
- (2016) Cheryl Taylor-Kashton et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia
- (2016) Thomas B. Alexander et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
- (2016) Albiruni R. Abdul Razak et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma
- (2016) Mrinal M. Gounder et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
- (2016) Joel G. Turner et al. Journal of Hematology & Oncology
- Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death
- (2016) Trinayan Kashyap et al. Oncotarget
- XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
- (2016) Joel G. Turner et al. Oncotarget
- Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia
- (2015) Z. A. Hing et al. BLOOD
- Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds
- (2015) Marsha Crochiere et al. BMC CANCER
- Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor
- (2015) S. Rosebeck et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started